Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1158
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 569
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 243
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 229
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
Sadiya S. Khan, Josef Coresh, Michael Pencina, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1982-2004
Closed Access | Times Cited: 190
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi, Kailei Nong, Per Olav Vandvik, et al.
BMJ (2023), pp. e074068-e074068
Open Access | Times Cited: 167
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 97
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
Nikita Simms-Williams, Nir Treves, Hui Yin, et al.
BMJ (2024), pp. e078242-e078242
Open Access | Times Cited: 40
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 37
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 23
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 22
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of its Pathology
Lisa C. Heather, Keshav Gopal, Nikola Srnic, et al.
Diabetes (2024) Vol. 73, Iss. 5, pp. 659-670
Closed Access | Times Cited: 17
What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances
Kimio Watanabe, Emiko Sato, Eikan Mishima, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 570-570
Open Access | Times Cited: 50
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
G.B. John Mancini, Eileen O’Meara, Shelley Zieroth, et al.
Canadian Journal of Cardiology (2022) Vol. 38, Iss. 8, pp. 1153-1167
Open Access | Times Cited: 44
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
Harold Bays, Shagun Bindlish, Tiffany Lowe Clayton
Obesity Pillars (2023) Vol. 5, pp. 100056-100056
Open Access | Times Cited: 32
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. Riley, Hani Essa, Philip Austin, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2897-2909
Open Access | Times Cited: 30
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102181-102181
Open Access | Times Cited: 25
Recent successes in heart failure treatment
Carolyn S.P. Lam, Kieran F. Docherty, Jennifer E. Ho, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2424-2437
Closed Access | Times Cited: 24
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
Paschalis Karakasis, Dimitrios Patoulias, George Kassimis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 27, pp. 2109-2119
Closed Access | Times Cited: 10
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top